Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Recruiting · NCT04704947 · Interventional (participants receive a specific treatment) · Lead sponsor: Sherief Abd-Elsalam
View the official record on ClinicalTrials.gov →Interventions studied
alendronate sodiumcardio-selective beta blocker groupnonselective beta blocker
What this trial is about
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Who can take part
Age range
50 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- • Male \& female osteoporotic patient aged ≥ 50 years
- Hypertensive \& normotensive patients
- BMD T-score ≥ 2.5 or more SD below peak bone mass
Exclusion criteria
- Patients on drugs that may improve osteoporosis disease state such as:
- Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.
- Patients on drugs that may worsen osteoporosis disease state such as:
- Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.
Where it is running
1 location listed.
- Sherief Abd-Elsalam - Tanta, Egypt